Sep 23, 2026

Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics:

• Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00)
• Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20)
• DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strategies in patients with MM in the second- and later-line settings (9:20)
• Monitoring for and management of belamaf-related ocular toxicities (12:29)
• Phase I DREAMM-9 trial of belamaf in combination with bortezomib/lenalidomide/dexamethasone (RVd) for transplant-ineligible newly diagnosed MM (16:23)
• Ongoing trials evaluating alternative belamaf dosing; practical considerations and recommendations for the administration of belamaf (19:07)

CME information and select publications